Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

VivoSim Labs, Inc. - Common Stock (NQ:VIVS)

0.2675 +0.0054 (+2.06%)
Streaming Delayed Price Updated: 10:39 AM EDT, Sep 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about VivoSim Labs, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
VivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs
New data presented in Vienna highlights long-term repeat-dose modeling, mechanistic GI barrier profiling, and deconvolution of payload- and linker-dependent toxicities for complex modalities 
From VivoSim Labs, Inc.
Via GlobeNewswire
News headline image
Catch the Danger, Spare the Cure: Why VivoSim’s (NASDAQ: VIVS) 90%/95% Toxicity Results Matter
Via AB Newswire
Topics Artificial Intelligence
News headline image
VivoSim Labs (NASDAQ: VIVS): Predicting Drug Toxicity Before Human Clinical Trials
Via AB Newswire
News headline image
VivoSim Labs (NASDAQ: VIVS) Opens New Pharma Opportunity
Via AB Newswire
News headline image
Microcaps GPRO, FLYE, HKPD, VIVS to Watch Now
Via AB Newswire
Topics Artificial Intelligence Supply Chain
News headline image
VivoSim Labs to Add Rat Liver Model to NAMkind Platform
New cross-species capability is designed to help pharma distinguish rat-specific liver toxicity from risks that may translate to humans 
From VivoSim Labs, Inc.
Via GlobeNewswire
News headline image
IGC Pharma (NYSE: IGC) Target Raised on Alzheimer’s 2027 Outlook
Via AB Newswire
Topics Artificial Intelligence
News headline image
VivoSim Labs (NASDAQ: VIVS): 10,000 Compounds to 1 Drug with AI-Powered 3D Human Toxicology
Via AB Newswire
Topics Artificial Intelligence
News headline image
Nasdaq 30’s VIVS, IGC, RIME, AIXI Stocks Now
Via AB Newswire
Topics Artificial Intelligence
News headline image
VivoSim Labs (NASDAQ: VIVS) Research Report Highlights AI-Powered Drug Toxicity Platform, FDA NAM Momentum
Via AB Newswire
Topics Animal Testing Artificial Intelligence
News headline image
VivoSim Labs (NASDAQ: VIVS) Among IGC, OSRH, IVF as FDA-Backed Human-Based Testing Gains Momentum
Via AB Newswire
Topics Animal Testing Artificial Intelligence
News headline image
VivoSim Labs (NASDAQ: VIVS) Emerges in Drug Toxicity Market as Revenue Growth Guidance Tops 500% – Plus More In Focus
Via AB Newswire
Topics Animal Testing Artificial Intelligence
News headline image
Oversold Stocks TOON, RMCF, PRSO, OFAL Offer Opportunity – See Why Inside
Via AB Newswire
Topics Artificial Intelligence
News headline image
VivoSim Provides Financial and Listing Compliance Update
From VivoSim Labs, Inc.
Via GlobeNewswire
In today's session, these stocks are experiencing unusual volume. ↗
Via Chartmill
MissionIRNewsBreaks – VivoSim Labs, Inc. (NASDAQ: VIVS) Announces $4 Million Private Placement
Via Investor Brand Network
Topics Animal Testing
News headline image
VivoSim Enters China with First Commercial Sales of NAMkind™ Toxicology Screening and Efficacy Testing Services
Initial customer wins bring VivoSim’s human-relevant liver and GI testing to the world’s second-largest pharmaceutical market 
From VivoSim Labs, Inc.
Via GlobeNewswire
In today's session, these stocks are experiencing unusual volume. ↗
Via Chartmill
Thursday's session: top gainers and losers ↗
Via Chartmill
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
News headline image
VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional Investor
From VivoSim Labs, Inc.
Via GlobeNewswire
News headline image
VivoSim Receives $5M Milestone Payment from Eli Lilly; Provides Guidance That It Expects Revenue Growth of 500%+ in FY2027
From VivoSim Labs, Inc.
Via GlobeNewswire
News headline image
VivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology Meeting
VivoSim Demonstrates Leadership in Field through AI-enabled NAMkind™ Liver and Intestine with High Accuracy Results, Including for Antibody Drug Conjugates (ADCs) 
From VivoSim Labs, Inc.
Via GlobeNewswire
News headline image
VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal Testing
VivoSim’s NAMkind™ Intestinal Model combined with AI prediction tools yields high-accuracy results 
From VivoSim Labs, Inc.
Via GlobeNewswire
Which stocks are moving before the opening bell on Wednesday? ↗
Via Chartmill
News headline image
VivoSim Announces Pricing of up to a $4 Million Public Offering
From VivoSim Labs, Inc.
Via GlobeNewswire
News headline image
VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs
ADCs are a major new market; Company demonstrates ability to discern antibody toxicity from payload toxicity and show differential linker chemistry toxicity 
From VivoSim Labs, Inc.
Via GlobeNewswire
News headline image
VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales
Veteran business development leader with deep expertise in human-relevant NAM and spheroid-based in vitro services to spearhead commercial growth along the US East Coast, deepening VivoSim’s reach with... 
From VivoSim Labs, Inc.
Via GlobeNewswire
News headline image
VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San Diego
Company produces thorough reference testing on Antibody Drug Conjugates, showing high correlation with clinical liver and intestinal toxicity and side effects 
From VivoSim Labs, Inc.
Via GlobeNewswire
News headline image
Why Is VIVS Stock Up 79% Today? ↗
VivoSims said on Friday that it has signed JCBio as an authorized distributor in Korea and Tekon Biotech as an authorized distributor in China for its NAMKind human-based toxicology services. 
Via Stocktwits
Topics Animal Testing
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.